NCT04787562 - Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 25, 2021

Primary Completion Date

October 30, 2021

Study Completion Date

February 28, 2022

Conditions

Bacterial Infections

Interventions

DRUG

XNW4107, Imipenem/Cilastatin

"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"

DRUG

XNW4107, Imipenem/Cilastatin

"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"

DRUG

XNW4107, Imipenem/Cilastatin

"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"

DRUG

XNW4107, Imipenem/Cilastatin

"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"

DRUG

XNW4107, Imipenem/Cilastatin

"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"

Trial Locations (2)

Division of Clinical Pharmacology (DCP), University of Miami, Miami

Orlando Clinical Research Center (OCRC), Orlando